From Acupuncture to Zinc: The Role of Complementary Therapies in Prostate Cancer

Speaker: Dr. Lynda Balneaves
Original Date: Tuesday January 6, 2015
 
This webinar will provide you with:
  • A basic understanding of the evidence regarding the role of popular complementary therapies in treating and managing prostate cancer.
  • Advice about how to make safe and informed decisions about complementary therapies.
  • Where to find credible information about complementary therapies.



Speaker – Dr. Lynda G. Balneaves, RN, PhD

Associate Professor

lyndabalneaves.jpgDr. Lynda Balneaves is an Associate Professor in the Department of Psychiatry in the University of Toronto and inaugural Director of the Centre of Integrative Medicine, a collaboration of the Faculty of Medicine and the Leslie Dan Faculty of Pharmacy, University of Toronto, as well as The Scarborough Hospital. She also holds the Kwok Yuen and Betty Ho Chair in Integrative Medicine at the University of Toronto and is a Scientist in the Department of Psychosocial Oncology and Palliative Care at the Princess Margaret Cancer Centre.

Dr. Balneaves has held a Canadian Institutes of Health Research (CIHR) New Investigator Award (2008-2013) and is a former Canadian Cancer Society Scholar Award recipient (2004-2008). She received the Award of Excellence in Nursing Research from the College of Registered Nurses of British Columbia in 2012. She is an author on over 60 academic publications and 3 book chapters and has presented her work internationally and nationally.

Currently, Dr. Balneaves the Secretary and executive board member of the Society for Integrative Oncology (SIO). She is also a board member of the International Society for Complementary Medicine Research (ISCMR).

For the past 20 years, Dr. Balneaves has focused her research program on knowledge translation and supporting informed treatment decisions in people interested in using complementary therapies. Since 2007, Dr. Balneaves has been the Principal Investigator of the Complementary Medicine Education and Outcomes (CAMEO) research program, which has focused on the development and evaluation of education and decision support interventions aimed at helping cancer patients and health professionals make evidence-based decisions about complementary therapies. She is also active in health services and policy research related to medical cannabis and is currently the Co-Principal Investigator of the CANARY Study, a longitudinal mixed method study that is exploring Canadians’ experience of accessing medical cannabis following shifts in federal regulations.


About Expert Angle

Expert AngleExpert Angle is designed to expand our reach and address the many varied and complex questions that come with a prostate cancer diagnosis. These webinars will address topics important to men with prostate cancer along different points of the cancer care continuum and those within their circle of care as well as the general public and representatives from the clinical community.
 
The meetings are hosted using interactive on-line technology and feature leading experts in prostate cancer - making them accessible to anyone, regardless of their location, within Canada. The platform allows PCC to communicate directly with individuals in a variety of settings (i.e. in their homes, support group meetings, community centres) and geographic locations (i.e. urban, rural and remote locations) as well as measure engagement.   

View more Expert Angle webinars.

 








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive